The American Society of Hematology sent an update today. Probably more along the lines of “background reading” than directly relevant to me, but an update on myeloma is always useful.
 |
EHA25 Virtual: Phase I Trial Supports CC-92480 for Heavily Pretreated Myeloma Results from a first-in-human trial of CC-92480 plus dexamethasone in patients with relapsed/refractory myeloma show a manageable safety profile and promising efficacy. |
 |
Belantamab Mafodotin-blmf Approved for Relapsed/Refractory Multiple Myeloma Approval was based on results from DREAMM-2, in which treatment with belantamab mafodotin-blmf 2.5 mg/kg every 3 weeks led to a clinically meaningful response in 31% of patients. |
|
EHA25 Virtual: Idecabtagene Vicleucel Demonstrates Deep, Durable Responses in Relapsed/Refractory Myeloma The BCMA-targeted CAR T-cell therapy induced responses in nearly 75% of patients with triple-class-exposed myeloma. |
No comments:
Post a Comment